

e-Therapeutics plc ("e-Therapeutics" or the "Company")

Re-statement of Directors' Interests

Following the successful completion of the Placings announced on 15 March 2011, the interests of the Directors of the Company are as follows:

Director	Title	Number of Shares	Percentage Post Placing
Prof. Malcolm Young ⁽¹⁾	Chief Executive Officer	20,620,482	15.03%
Johnny Cordiner ⁽¹⁾	Finance Director	362,060	0.30%
Novotech ⁽¹⁾	(n/a - see footnote)	1,640,236	1.20%
Stephen Self	Development Director	86,413	0.06%
Prof. Oliver James	Non-executive Chairman	38,500	0.03%
Brad Hoy	Non-executive Director	0	0.00%

- (1) The Novotech holding in the Company comprises holdings by Novotech Investment Limited ("NIL") and Novotech Syndicate LLP ("NSL"). Malcolm Young and John Cordiner are each directors and shareholders of NIL and equity partners in NSL.

Through their interests in the Novotech entities, each of Malcolm Young and John Cordiner indirectly holds a further 428,512 shares in e-Therapeutics, representing 0.3% of the total issued share capital.

For more information, please contact:

e-Therapeutics plc

Malcolm Young / John Cordiner

Tel: +44 (0) 191 233 1317

E-mail: info@etherapeutics.co.uk

www.etherapeutics.co.uk

Panmure Gordon (UK) Limited

Andrew Burnett / Aubrey Powell

Tel: +44 (0) 20 7459 3600

www.panmure.com